-
1
-
-
84863707351
-
Cancer treatment and survivorship statistics 2012
-
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220-41.
-
(2012)
CA Cancer J Clin
, vol.62
, pp. 220-241
-
-
Siegel, R.1
Desantis, C.2
Virgo, K.3
Stein, K.4
Mariotto, A.5
Smith, T.6
-
2
-
-
77249135465
-
Treatment for metastatic malignant melanoma: Old drugs and new strategies
-
Mouawad R, Sebert M, Michels J. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2010;74:27-39.
-
(2010)
Crit Rev Oncol Hematol
, vol.74
, pp. 27-39
-
-
Mouawad, R.1
Sebert, M.2
Michels, J.3
-
3
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
-
4
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
-
(2012)
N Engl J Med
, vol.366
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
Gonzalez, R.4
Pavlick, A.C.5
Weber, J.S.6
-
5
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
-
(2012)
N Engl J Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
Gonzalez, R.4
Kefford, R.F.5
Sosman, J.6
-
6
-
-
84865316603
-
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti- CD137, and anti-PD1
-
Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti- CD137, and anti-PD1. J Immunotoxicol 2012;9:241-7.
-
(2012)
J Immunotoxicol
, vol.9
, pp. 241-247
-
-
Simeone, E.1
Ascierto, P.A.2
-
7
-
-
84867539636
-
RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy
-
Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012;2012: 354191.
-
(2012)
Dermatol Res Pract
, vol.2012
, pp. 354191
-
-
Yajima, I.1
Kumasaka, M.Y.2
Thang, N.D.3
Goto, Y.4
Takeda, K.5
Yamanoshita, O.6
-
8
-
-
41049114747
-
How to make a melanoma: What do we know of the primary clonal events?
-
Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008;21:27-38.
-
(2008)
Pigment Cell Melanoma Res
, vol.21
, pp. 27-38
-
-
Bennett, D.C.1
-
9
-
-
33947213963
-
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma
-
DOI 10.1158/0008-5472.CAN-06-3665
-
Namkoong J, Shin SS, Lee HJ. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007;67: 2298-305. (Pubitemid 46424250)
-
(2007)
Cancer Research
, vol.67
, Issue.5
, pp. 2298-2305
-
-
Namkoong, J.1
Shin, S.-S.2
Hwa, J.L.3
Marin, Y.E.4
Wall, B.A.5
Goydos, J.S.6
Chen, S.7
-
10
-
-
0037994016
-
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia
-
DOI 10.1038/ng1148
-
Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34: 108-12. (Pubitemid 36548800)
-
(2003)
Nature Genetics
, vol.34
, Issue.1
, pp. 108-112
-
-
Pollock, P.M.1
Cohen-Solal, K.2
Sood, R.3
Namkoong, J.4
Martino, J.J.5
Koganti, A.6
Zhu, H.7
Robbins, C.8
Makalowska, I.9
Shin, S.-S.10
Marin, Y.11
Roberts, K.G.12
Yudt, L.M.13
Chen, A.14
Cheng, J.15
Incao, A.16
Pinkett, H.W.17
Graham, C.L.18
Dunn, K.19
Crespo-Carbone, S.M.20
Mackason, K.R.21
Ryan, K.B.22
Sinsimer, D.23
Goydos, J.24
Reuhl, K.R.25
Eckhaus, M.26
Meltzer, P.S.27
Pavan, W.J.28
Trent, J.M.29
Chen, S.30
more..
-
11
-
-
43549096176
-
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation
-
DOI 10.1111/j.1755-148X.2008.00452.x
-
Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 2008;21:368-78. (Pubitemid 351678078)
-
(2008)
Pigment Cell and Melanoma Research
, vol.21
, Issue.3
, pp. 368-378
-
-
Shin, S.-S.1
Namkoong, J.2
Wall, B.A.3
Gleason, R.4
Lee, H.J.5
Chen, S.6
-
12
-
-
57349145304
-
Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma
-
Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M, et al. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 2008;27:7162-70.
-
(2008)
Oncogene
, vol.27
, pp. 7162-7170
-
-
Ohtani, Y.1
Harada, T.2
Funasaka, Y.3
Nakao, K.4
Takahara, C.5
Abdel-Daim, M.6
-
13
-
-
80053073264
-
Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice
-
Choi KY, Chang K, Pickel JM, Badger JD, Roche KW. Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci U S A 2011;108:15219-24.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 15219-15224
-
-
Choi, K.Y.1
Chang, K.2
Pickel, J.M.3
Badger, J.D.4
Roche, K.W.5
-
14
-
-
0035952679
-
Autocrine and paracrine signaling through neuropeptide receptors in human cancer
-
DOI 10.1038/sj.onc.1204183
-
Heasley L. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001;20:1563-9. (Pubitemid 32336844)
-
(2001)
Oncogene
, vol.20
, pp. 1563-1569
-
-
Heasley, L.E.1
-
16
-
-
66649107219
-
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma
-
Yip D, Le MN, Chan JLK, Lee JH, Mehnert JA, Yudd A, et al. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 2009;15:3896-902.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3896-3902
-
-
Yip, D.1
Le, M.N.2
Chan, J.L.K.3
Lee, J.H.4
Mehnert, J.A.5
Yudd, A.6
-
17
-
-
84876181799
-
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma
-
abstr 8557)
-
Mehnert JM, Wen Y, Lee JH, Pruski-Clark L, Shih W, Chen S, et al. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma. J Clin Oncol 2011;29 (suppl; abstr 8557).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Mehnert, J.M.1
Wen, Y.2
Lee, J.H.3
Pruski-Clark, L.4
Shih, W.5
Chen, S.6
-
18
-
-
77955715672
-
The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells
-
Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen- Solal KA, et al. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 2010;130:2240-9.
-
(2010)
J Invest Dermatol
, vol.130
, pp. 2240-2249
-
-
Le, M.N.1
Chan, J.L.2
Rosenberg, S.A.3
Nabatian, A.S.4
Merrigan, K.T.5
Cohen- Solal, K.A.6
-
19
-
-
79955613321
-
A mathematical model for tumor volume evaluation using two-dimensions
-
Feldman J, Goldwasser R, Mark S, Schwartz J, Orion I. A mathematical model for tumor volume evaluation using two-dimensions. J App Quan Methods 2009;4:455-62.
-
(2009)
J App Quan Methods
, vol.4
, pp. 455-462
-
-
Feldman, J.1
Goldwasser, R.2
Mark, S.3
Schwartz, J.4
Orion, I.5
-
20
-
-
84873030152
-
External Qi of Yan Xin Qigong inhibits activation of Akt,Erk1/2 and NF-&boxtimes B and induces cell cycle arrest and apoptosis in colorectal cancer cells
-
Yan X, Shen H, Jiang H, Hu D, Wang J, Wu X. External Qi of Yan Xin Qigong inhibits activation of Akt, Erk1/2 and NF-& boxtimes B and induces cell cycle arrest and apoptosis in colorectal cancer cells. Cell Physiol Biochem 2013;31:113-22.
-
(2013)
Cell Physiol Biochem
, vol.31
, pp. 113-122
-
-
Yan, X.1
Shen, H.2
Jiang, H.3
Hu, D.4
Wang, J.5
Wu, X.6
-
22
-
-
0009663357
-
A multiple comparison procedure for comparing several treatments with a control
-
Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-121.
-
(1955)
J Am Stat Assoc
, vol.50
, pp. 1096-1121
-
-
Dunnett, C.W.1
-
23
-
-
0025181577
-
A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells
-
O'Connell K, Edidin M. A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 1990;144:521-5. (Pubitemid 20036078)
-
(1990)
Journal of Immunology
, vol.144
, Issue.2
, pp. 521-525
-
-
O'Connell, K.A.1
Edidin, M.2
-
24
-
-
77954295386
-
HIF-1a mediates the induction of IL-8 and VEGF expression on infection with Afa/Dr diffusely adhering E. Coli and promotes EMT-like behaviour
-
Cane G, Ginouvès A, Marchetti S, Buscá R, Pouysségur J, Berra E, et al. HIF-1a mediates the induction of IL-8 and VEGF expression on infection with Afa/Dr diffusely adhering E. coli and promotes EMT-like behaviour. Cell Microbiol 2010;12:640-53.
-
(2010)
Cell Microbiol
, vol.12
, pp. 640-653
-
-
Cane, G.1
Ginouvès, A.2
Marchetti, S.3
Buscá, R.4
Pouysségur, J.5
Berra, E.6
-
25
-
-
58049216350
-
Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2
-
Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1α and 2αon mTORC1 and mTORC2. J Biol Chem 2008;283:34495-9.
-
(2008)
J Biol Chem
, vol.283
, pp. 34495-34499
-
-
Toschi, A.1
Lee, E.2
Gadir, N.3
Ohh, M.4
Foster, D.A.5
-
26
-
-
63849178889
-
Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer
-
Chen Y, Zhao C, Li W. Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res 2009;28:8.
-
(2009)
J Exp Clin Cancer Res
, vol.28
, pp. 8
-
-
Chen, Y.1
Zhao, C.2
Li, W.3
-
27
-
-
0037414180
-
YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1
-
Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natil Cancer Inst 2003;95:516-25. (Pubitemid 36511622)
-
(2003)
Journal of the National Cancer Institute
, vol.95
, Issue.7
, pp. 516-525
-
-
Yeo, E.-J.1
Chun, Y.-S.2
Cho, Y.-S.3
Kim, J.4
Lee, J.-C.5
Kim, M.-S.6
Park, J.-W.7
-
28
-
-
79951682606
-
Hypoxia-inducible factors in mantle cell lymphoma: Implication for an activated mTORC1→ HIF-1α pathway
-
Argyriou P, Papageorgiou S, Panteleon V, Psyrri A, Bakou V, Pappa V, et al. Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1 →HIF-1α pathway. Ann Hematol 2011;90: 315-22.
-
(2011)
Ann Hematol
, vol.90
, pp. 315-322
-
-
Argyriou, P.1
Papageorgiou, S.2
Panteleon, V.3
Psyrri, A.4
Bakou, V.5
Pappa, V.6
-
30
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
-
(2011)
Nature
, vol.480
, pp. 387-390
-
-
Poulikakos, P.I.1
Persaud, Y.2
Janakiraman, M.3
Kong, X.4
Ng, C.5
Moriceau, G.6
-
31
-
-
84864994126
-
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma
-
Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 2012;287:28087-98.
-
(2012)
J Biol Chem
, vol.287
, pp. 28087-28098
-
-
Yadav, V.1
Zhang, X.2
Liu, J.3
Estrem, S.4
Li, S.5
Gong, X.Q.6
-
32
-
-
84855372404
-
Dissection of aberrant GPCR signaling in tumorigenesis - A systems biology approach
-
Wu J, Xie N, Zhao X, Nice EC, Huang C. Dissection of aberrant GPCR signaling in tumorigenesis - a systems biology approach. Cancer Genomics Proteomics 2012;9:37-50.3
-
(2012)
Cancer Genomics Proteomics
, vol.9
, pp. 373-503
-
-
Wu, J.1
Xie, N.2
Zhao, X.3
Nice, E.C.4
Huang, C.5
-
33
-
-
38049084115
-
Metabotropic glutamate receptors: Phosphorylation and receptor signaling
-
Kim CH, Lee J, Lee JY, Roche KW. Metabotropic glutamate receptors: Phosphorylation and receptor signaling. J Neurosci Res 2008;86:1-10.
-
(2008)
J Neurosci Res
, vol.86
, pp. 1-10
-
-
Kim, C.H.1
Lee, J.2
Lee, J.Y.3
Roche, K.W.4
-
34
-
-
80054997116
-
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma
-
Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 2011;43: 1119-26.
-
(2011)
Nat Genet
, vol.43
, pp. 1119-1126
-
-
Prickett, T.D.1
Wei, X.2
Cardenas-Navia, I.3
Teer, J.K.4
Lin, J.C.5
Walia, V.6
-
36
-
-
38549168468
-
Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: Inhibition by riluzole
-
DOI 10.1167/iovs.07-0395
-
Yoo MH, Yoon YH, Chung H, Cho KS, Koh JY. Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole. Invest Ophthalmol Vis Sci 2007;48:5671-6. (Pubitemid 351260870)
-
(2007)
Investigative Ophthalmology and Visual Science
, vol.48
, Issue.12
, pp. 5671-5676
-
-
Yoo, M.-H.1
Young, H.Y.2
Chung, H.3
Kyung, S.C.4
Koh, J.-Y.5
-
37
-
-
33644814322
-
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo
-
DOI 10.1167/iovs.05-0376
-
Yoo MH, Hyun HJ, Koh JY, Yoon YH. Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci 2005;46:4780-7. (Pubitemid 44264584)
-
(2005)
Investigative Ophthalmology and Visual Science
, vol.46
, Issue.12
, pp. 4780-4787
-
-
Yoo, M.H.1
Hyun, H.-J.2
Koh, J.-Y.3
Yoon, Y.H.4
-
38
-
-
0037277741
-
Vascular endothelial growth factors and angiogenesis in eye disease
-
DOI 10.1016/S1350-9462(02)00043-5, PII S1350946202000435
-
WitmerAN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
-
(2003)
Progress in Retinal and Eye Research
, vol.22
, Issue.1
, pp. 1-29
-
-
Witmer, A.N.1
Vrensen, G.F.J.M.2
Van Noorden, C.J.F.3
Schlingemann, R.O.4
-
39
-
-
33747462081
-
Expression and sequences of genes encoding glutamate receptors and transporters in primate retina determined using 30-end amplication polymerase chain reaction
-
Hanna MC, Calkins DJ. Expression and sequences of genes encoding glutamate receptors and transporters in primate retina determined using 30-end amplification polymerase chain reaction. Mol Vis 2006;12:961-76. (Pubitemid 44256422)
-
(2006)
Molecular Vision
, vol.12
, pp. 961-976
-
-
Hanna, M.C.1
Calkins, D.J.2
-
40
-
-
0036310021
-
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma
-
Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang X, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002;161:125-34. (Pubitemid 34760778)
-
(2002)
American Journal of Pathology
, vol.161
, Issue.1
, pp. 125-134
-
-
Huang, S.1
Mills, L.2
Mian, B.3
Tellez, C.4
McCarty, M.5
Yang, X.-D.6
Gudas, J.M.7
Bar-Eli, M.8
-
41
-
-
50049089470
-
Tumor immunotherapy in melanoma: Strategies for overcoming mechanisms of resistance and escape
-
Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M. Tumor Immunotherapy in Melanoma: Strategies for Overcoming Mechanisms of Resistance and Escape. Am J Clin Dermatol 2008;9:307-11.
-
(2008)
Am J Clin Dermatol
, vol.9
, pp. 307-311
-
-
Zigler, M.1
Villares, G.J.2
Lev, D.C.3
Melnikova, V.O.4
Bar-Eli, M.5
-
42
-
-
70450175957
-
Targeting angiogenesis: Progress with anti- VEGF treatment with large molecules
-
Grothey A, Galanis E. Targeting angiogenesis: progress with anti- VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6:507-18.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 507-518
-
-
Grothey, A.1
Galanis, E.2
-
43
-
-
75949093518
-
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
-
Mehnert JM, McCarthyMM,Jilaveanu L, Flaherty KT, Aziz S,CampRL, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Human Pathology 2010; 41:375-84.
-
(2010)
Human Pathology
, vol.41
, pp. 375-384
-
-
Mehnert, J.M.1
McCarthy, M.M.2
Jilaveanu, L.3
Flaherty, K.T.4
Aziz, S.5
Camp, R.L.6
-
44
-
-
84872956413
-
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N0775
-
Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT III, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N0775. Cancer 2013;119:586-92.
-
(2013)
Cancer
, vol.119
, pp. 586-592
-
-
Kottschade, L.A.1
Suman, V.J.2
Perez, D.G.3
McWilliams, R.R.4
Kaur, J.S.5
Amatruda III, T.T.6
-
45
-
-
84875466657
-
Persistent current blockers of voltage-gated sodium channels: A clinical opportunity for controlling metastatic disease
-
Djamgoz M, Onkal R. Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease. Recent Pat Anticancer Drug Discov 2013;8:66-84.
-
(2013)
Recent Pat Anticancer Drug Discov
, vol.8
, pp. 66-84
-
-
Djamgoz, M.1
Onkal, R.2
|